evipedia.aidev
← Back

DFPP vs. TPE for Health & Longevity

Evidence Review created on 08/30/2026 using AI4L / Grok 4.5

Also known as: Double Filtration Plasmapheresis vs. Therapeutic Plasma Exchange, Double-Filtration Plasmapheresis vs. Plasma Exchange, Cascade Filtration vs. Therapeutic Plasma Exchange, DFPP vs. PLEX, DFPP vs. PE, Membrane Differential Filtration vs. Centrifugal Plasma Exchange, INUSpheresis vs. Therapeutic Plasma Exchange

Motivation

Double filtration plasmapheresis (DFPP) and therapeutic plasma exchange (TPE) are two clinic-based methods for stripping selected contents out of circulating plasma and returning the blood cells. Plasma exchange discards plasma in bulk and replaces the volume, usually with albumin solution. Double filtration uses a second filter so large proteins are held back while much of the albumin returns, which cuts the need for replacement fluid. Longevity interest grew after mouse work showed that diluting old plasma, rather than infusing young plasma, restored tissue repair.

Clinics now sell both procedures to healthy adults as a way to clear age-elevated blood factors. One randomized trial of plasma exchange with albumin reported a shift in blood-based estimates of biological age; a separate trial of plasma donation without albumin replacement reported movement in the opposite direction. In autoimmune kidney disease, head-to-head cohorts have found similar antibody lowering with fewer allergic events when the double-filter method is used.

This review examines how the two procedures differ in what they remove, the human evidence for healthspan-relevant benefits and harms, the role of replacement fluid, cost, access, and how response is tracked.

Benefits - Risks - Protocol - Conclusion

High-level sources that distinguish bulk plasma exchange from selective double filtration and set the longevity dilution hypothesis in context.

No dedicated DFPP-versus-TPE overview was found from Peter Attia, Chris Kresser, or Life Extension Magazine; FoundMyFitness, Huberman Lab, and Lifespan.io are represented above.

Grokipedia

Plasmapheresis

Grokipedia’s dedicated plasma-exchange page covers procedure types, indications, donation versus therapy, and adverse effects. No page compares DFPP with TPE; a related Rheopheresis entry describes double-membrane filtration.

Examine

No Examine.com article on DFPP or TPE was found. Examine.com focuses on supplements and nutrition, not extracorporeal procedures.

ConsumerLab

No ConsumerLab review of DFPP or TPE was found. ConsumerLab tests dietary supplements and related consumer products, not apheresis procedures.

Systematic Reviews

Systematic reviews and meta-analyses that cover double-filter or bulk plasma-exchange efficacy and the main procedure harms.

Mechanism of Action

Both procedures are extracorporeal (blood leaves the body, is processed, and returns). Cells are separated from plasma by centrifuge or a first membrane. In TPE the plasma is discarded and the volume is replaced, usually with 5% human albumin in saline, sometimes with fresh frozen plasma when clotting proteins must be returned. A one-volume exchange removes about 65% of a dissolved plasma solute; 1–1.5 plasma volumes per session is typical.

DFPP adds a second filter (plasma fractionator). Molecules larger than its pores — low-density lipoprotein, lipoprotein(a), immunoglobulin M, fibrinogen, immune complexes — are discarded. Albumin (about 66 kilodaltons) and many smaller proteins return, so little replacement fluid is needed. Pore size sets the cut: tighter filters remove more immunoglobulin G (IgG); looser ones act more like lipid apheresis.

The Conboy-lab longevity hypothesis is dilution, not young-factor transfusion. Age-elevated circulating inhibitors are thought to block tissue repair. Mouse “neutral blood exchange” with saline-albumin reproduced multi-tissue rejuvenation without young plasma. Bulk TPE with albumin is the closer human analog because mid-size proteins leave with the plasma. DFPP efficiently removes lipoproteins and very large proteins but can spare mid-size cytokines that pass the fractionator. A competing view holds that adding intravenous immunoglobulin after exchange reshapes immune-cell mix beyond dilution alone.

These are devices, not drugs. Fibrinogen recovers over about 48 hours (half-life roughly 3–4 days); immunoglobulin G and albumin recover over 1–3 weeks.

Historical Context & Evolution

Plasma removal for disease dates to early-twentieth-century plasmapheresis. Automated centrifugal exchange became standard treatment for thrombotic thrombocytopenic purpura (a clotting emergency with low platelets and tiny-vessel clots), Guillain-Barré syndrome, myasthenia gravis, and anti-glomerular basement membrane disease. The American Society for Apheresis (ASFA), whose members perform and bill these procedures, issues indication lists; those lists are practice guides, not independent proof. Membrane plasma separation spread in Japan, Germany, and dialysis units.

Agishi and colleagues in 1980s Japan developed DFPP to cut dependence on donor plasma after transfusion-infection scares. Japan’s national insurance later listed many DFPP indications, including familial hypercholesterolemia and high lipoprotein(a). European wellness clinics later branded cascade filtration (including INUSpheresis) for “detox.” Filter-makers such as Asahi Kasei employ authors of widely cited DFPP reviews.

Longevity use followed heterochronic parabiosis (old and young mice sharing circulation). Irina and Michael Conboy’s work shifted the story from “young blood helps” to “old plasma hurts.” Ambrosia-style young-plasma products drew Food and Drug Administration warnings. The same hardware used for autoimmune TPE was then repositioned as plasma dilution with albumin. Dobri Kiprov’s group, Global Apheresis, and Circulate Health — parties that sell or perform elective TPE — ran the first human aging-biomarker series and the 2025 randomized clock trial. Grifols, which sells albumin, funded the Alzheimer’s AMBAR exchange program. Parallel “plasma donation as rejuvenation” trials without albumin replacement produced the opposite clock signal, which is why replacement fluid, not the brand of filter, is now the live mechanistic dispute.

Expected Benefits

Benefits below are framed for adults already optimizing lipids, inflammation, and neurologic risk who are considering elective apheresis, not for the average untreated patient.

High 🟩 🟩 🟩

Lowering of low-density lipoprotein cholesterol and lipoprotein(a)

Double filtration plasmapheresis is an established lipoprotein-apheresis method: the second filter traps large particles including low-density lipoprotein cholesterol (LDL-C, the main artery-clogging cholesterol particle) and lipoprotein(a) (Lp(a), a genetic lipid particle). A systematic review of LDL apheresis in familial hypercholesterolemia reported mean per-session LDL-C reductions of about 57–75% in homozygous and 58–63% in heterozygous disease. TPE also strips these particles but is not the usual lipid platform. Levels rebound over days to weeks.

Magnitude: About 57–75% (homozygous) and 58–63% (heterozygous) mean per-session LDL-C reduction with lipoprotein apheresis, including DFPP platforms (Wang et al., 2016).

Medium 🟩 🟩

Slower functional decline in moderate Alzheimer’s disease (TPE with albumin)

The AMBAR randomized trial (n = 347) tested plasma exchange with albumin, then monthly low-volume exchange, with or without intravenous immunoglobulin, versus sham. Treated people with moderate Alzheimer’s disease (a dementia of amyloid and tau pathology) had less decline on validated daily-function and global scales; mild disease showed little separation. Grifols, an albumin manufacturer, funded the work. DFPP was not the study procedure, so this signal applies to bulk exchange plus albumin, not to double filtration.

Magnitude: About 52% less decline on a daily-function scale and 71% less decline on a global clinical scale versus sham at 14 months in the pooled exchange arms, concentrated in moderate disease (Boada et al., 2020).

Pathogenic-antibody lowering with DFPP comparable to TPE, with less replacement plasma

In anti-glomerular basement membrane (anti-GBM) nephritis and severe ANCA-associated vasculitis (AAV; autoimmune kidney diseases driven by circulating antibodies), retrospective cohorts found similar antibody drop and similar kidney or survival outcomes with DFPP versus TPE, while DFPP used far less donor plasma and, in one cohort, fewer allergy episodes. For a longevity user this is not a healthspan endpoint; it is the best head-to-head human comparison of what each machine actually removes.

Magnitude: In 58 anti-GBM patients, antibody levels fell from 136 to 27 AU/mL (DFPP) and 122 to 27 AU/mL (TPE); allergy 14% vs 43% (Liu et al., 2025). In 42 AAV patients with creatinine ≥500 μmol/L, plasma used per session was 600 mL vs 1,927 mL (Cheng et al., 2020).

Low 🟩

Modest C-reactive protein lowering with lipoprotein apheresis

A 2025 meta-analysis of lipoprotein apheresis (DFPP among the methods) found a small drop in C-reactive protein (CRP, a liver-made inflammation marker), mainly with longer treatment, and no consistent change in other cytokines. This is a hint, not a disease-outcome result.

Magnitude: Standardized mean difference −0.31 for CRP (95% confidence interval (CI) −0.44 to −0.18); other cytokines not significant (Hatami et al., 2025).

Speculative 🟨

Epigenetic-clock rejuvenation ⚠️ Conflicted

Albumin-TPE produced younger clock estimates versus sham, more so with immunoglobulin (Fuentealba et al., 2025); donation without replacement moved estimates older (Borsky et al., 2025). Net reading: replacement fluid, not filter type, likely sets direction.

Proteomic and immune-cell “younger” shift after repeated TPE

Leftover samples from eight people after ≥5 TPE sessions showed a younger-leaning plasma protein pattern and fewer senescent cell marks. Uncontrolled human biomarker data only; DFPP was not tested (Kim et al., 2022).

Multi-tissue rejuvenation from plasma dilution (mice)

Saline-albumin exchange in old mice improved muscle repair, hippocampal neuron birth, and liver fat/fibrosis without young plasma. Human functional equivalents have not been shown.

Microplastic and per- and polyfluoroalkyl substances (PFAS) clearance by DFPP

A 2025 INUSpheresis report and an ongoing paired-sample study (NCT07658443) ask whether double filtration lowers circulating plastics and PFAS. Pre/post particle counts are not yet an outcome trial.

Benefit-Modifying Factors

  • Baseline lipids: People with very high LDL-C or Lp(a) despite drugs have the clearest, replicated DFPP benefit; normal lipids leave little lipid signal to capture.

  • Starting inflammatory load: The 2025 TPE-plus-immunoglobulin clock analysis found larger molecular responses in those with worse baseline immune-aging marks, not in the already-healthy.

  • Alzheimer’s stage: AMBAR’s functional signal sat in moderate, not mild, disease; applying that result to unimpaired adults is an extrapolation.

  • APOE4: The Alzheimer’s-risk gene variant is relevant to who might care about that dementia signal; it does not decide TPE versus DFPP.

  • Sex: Mouse dilution work has reported sex-specific lifespan effects; human TPE aging trials are mixed-sex and too small to split protocol by sex.

  • Age and vessels: Older adults are the intended longevity users and were treated in AMBAR and Fuentealba, but fragile veins and heart disease change whether peripheral access is even possible.

  • Fractionator and replacement: A lipid-oriented DFPP filter will not dilute mid-size proteins the way albumin-TPE does; albumin versus no replacement appears to flip clock direction.

Potential Risks & Side Effects

Risks below are for elective, often repeated, outpatient sessions in otherwise ambitious adults, using disease-trial and registry rates where those are the only human numbers.

High 🟥 🟥 🟥

Centrifugal TPE is usually anticoagulated with citrate, which binds ionized calcium. Tingling, muscle cramp, corrected QT interval (heart-repolarization) change, and frank hypocalcemia are the most frequent chemistry events. A 2026 systematic review of regional citrate in TPE pooled hypocalcemia at about 18% of sessions (wide interval) and hypomagnesemia at about 46%. Membrane DFPP more often uses heparin, shifting the problem toward bleeding rather than citrate tetany (painful muscle spasm from low ionized calcium), but many mixed circuits still use citrate.

Magnitude: Pooled hypocalcemia 17.9% (95% CI 2.3–42.5%) and hypomagnesemia 45.6% (95% CI 25.9–66.0%) of citrate-TPE sessions (Liu et al., 2026).

Fibrinogen and clotting-factor depletion

TPE removes proteins of every size; DFPP preferentially removes large ones, but fibrinogen and factor XIII (a clot-stabilizing protein) fall with both. Comparative work found similar post/pre fibrinogen ratios for DFPP and TPE, with reconstitution about 0.8 g/L over a median 38 hours. Elective users who add training, travel, or procedures in that window carry a bleeding-and-clotting mismatch until levels recover.

Magnitude: Median post/pre fibrinogen in the same depleted range for DFPP and TPE; median reconstitution 0.8 g/L (interquartile 0.4–1.2) over ~38 hours (Marlu et al., 2021; Jouve et al., 2021).

Serious infection during intensive TPE courses

Bulk exchange strips immunoglobulin G. In ANCA vasculitis, a meta-analysis of randomized trials found TPE increased serious infections at 12 months (relative risk 1.27) while reducing kidney failure. Elective longevity series are smaller and healthier; they do not cancel an immunoglobulin-depletion mechanism that is dose- and frequency-dependent.

Magnitude: Relative risk 1.27 (95% CI 1.08–1.49) for serious infection at 12 months with TPE in AAV trials (Walsh et al., 2022).

Hypotension during the extracorporeal run

Volume shifts and vasovagal responses drop blood pressure while blood is outside the body. A neurology-TPE meta-analysis in sick inpatients reported hypotension in about 12% of people; elective peripheral-vein sessions run lower but are not zero. Longer DFPP runs extend time on the machine.

Magnitude: Hypotension about 12% of people in a 2,199-person autoimmune-neurology TPE synthesis (Tao et al., 2026); DFPP sessions ~219 vs ~117 minutes in one AAV comparison (Cheng et al., 2020).

Medium 🟥 🟥

Allergic and anaphylactoid reactions to replacement fluid (higher with TPE)

Albumin and especially fresh frozen plasma can trigger rash, bronchospasm, or anaphylaxis. DFPP needs little or no replacement, and a 2025 anti-GBM cohort reported fewer allergy episodes with DFPP than TPE. World Apheresis Association registry data put overall apheresis adverse events at 2.7% of procedures, severe 0.15%; replacement-fluid reactions sit inside that mix.

Magnitude: Allergy 13.64% vs 42.86% (DFPP vs TPE) in one 58-person cohort (Liu et al., 2025); registry any-event rate 2.7% and severe 0.15% of procedures (Vrielink et al., 2023).

Vascular-access hematoma, thrombosis, and line infection

Needles and catheters can bruise, clot, or infect. That is a different harm from on-machine hypotension. Elective users who stay on peripheral veins avoid central-line infection but still get needle-site problems. Registry totals mix access events with other reactions.

Magnitude: Registry any-event rate 2.7% and severe 0.15% of procedures, mixing access with other reactions rather than an access-only elective figure (Vrielink et al., 2023).

Low 🟥

Angiotensin-converting enzyme (ACE) inhibitor–related bradykinin reactions on some membranes

These blood-pressure drugs block bradykinin breakdown. Negatively charged membranes can generate bradykinin and produce flushing, hypotension, or shock if the drug was taken that day. This is a membrane-DFPP/membrane-TPE issue, preventable by holding the drug.

Magnitude: Not quantified in available studies. Evidence is mechanistic plus labeled warnings and LDL-apheresis case series rather than a pooled elective-TPE incidence (Koga et al., 1993).

Transient platelet drop (greater with centrifugal TPE)

Centrifugal TPE can sequester platelets in the bowl. Direct three-modality coagulation work showed bulk TPE lowers proteins of every size, while DFPP preferentially lowers large ones; platelets were not the primary endpoint. Isolated platelet dips are usually short-lived.

Magnitude: Not quantified in available studies. Comparative coagulation papers report protein-class differences, not a pooled elective platelet-bleed rate (Marlu et al., 2021).

Speculative 🟨

Faster epigenetic aging if plasma is removed without albumin replacement

A donor trial of repeated plasmapheresis without albumin or young plasma moved several DNA-methylation clocks older. Removing plasma without replacing albumin is not automatically rejuvenating.

Unknown cumulative harm from repeated elective immunoglobulin stripping

Healthy people repeating six-plus sessions per year have no decade-scale safety set. Theoretical risks include impaired vaccine responses and infection beyond the vasculitis-trial numbers.

Risk-Modifying Factors

  • Ionized calcium and magnesium: Low starting ionized calcium or magnesium raises citrate tetany risk; replacement during the run is the usual modifier.

  • Fibrinogen and recent procedures: Baseline fibrinogen below about 1.0–1.5 g/L, or surgery/dental work inside 48 hours, magnifies bleeding after either modality.

  • Immunoglobulin G stock: Low starting IgG, immunosuppressant use, or a dense session schedule increases infection risk after TPE more than after albumin-sparing DFPP.

  • Sex and body size: Smaller plasma volume means a “one-volume” exchange is a larger relative insult; citrate dose scales with processed volume.

  • Age and heart-lung reserve: Older adults in AMBAR tolerated exchange, but coronary disease, heart failure, and severe chronic lung disease are standard exclusions in elective trials.

  • Membrane plus ACE inhibitor: Last-day ACE-inhibitor use is a specific DFPP/membrane risk, not a centrifugal-albumin-TPE risk.

Key Interactions & Contraindications

  • ACE inhibitors (lisinopril, ramipril, enalapril): Absolute hold for 24 hours before membrane DFPP or membrane TPE (bradykinin hypotension). Severity: absolute periprocedural contraindication on those circuits. Mitigant: switch to an angiotensin-receptor blocker or hold and restart after.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel): Caution — additive bleeding once fibrinogen and factor XIII fall. Mitigant: check fibrinogen next day; delay elective procedures 48 hours.

  • Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs; ibuprofen, naproxen): Caution — over-the-counter pain/anti-inflammatory drugs add bleeding risk after clotting proteins fall. Mitigant: pause around the session if the indication allows.

  • Intravenous immunoglobulin: Additive immune modulation with TPE (used on purpose in AMBAR and Fuentealba); also a source of infusion reactions. Severity: monitor. Mitigant: give after, not during, the exchange if used.

  • Albumin-bound drugs (warfarin, phenytoin, valproate, some benzodiazepines): TPE can drop levels; DFPP less so for small drugs that return with albumin. Severity: monitor. Mitigant: retime critical-dose drugs after the session.

  • Antihypertensives and volume-active agents: Caution — hypotension on the circuit. Mitigant: hold the morning dose if pressure runs low.

  • Lipid-lowering drugs (statins, evolocumab, alirocumab, inclisiran): Additive LDL-C and Lp(a) lowering with DFPP, not a harm interaction. Severity: none; expected synergy.

  • Calcium and vitamin D supplements: Severity: monitor. Potentiating against citrate hypocalcemia if ionized calcium is low; not a substitute for on-circuit calcium.

  • Other apheresis or recent plasma donation: Additive protein loss. Severity: caution. Mitigant: space ≥7 days.

Populations who should avoid DFPP vs. TPE:

  • Hemodynamic instability, uncontrolled sepsis, or active major bleeding
  • No usable peripheral or central access
  • Known anaphylaxis to albumin, heparin, or the planned membrane
  • Active infection or untreated malignancy (elective longevity protocols)
  • Symptomatic coronary disease, decompensated heart failure, or severe restrictive lung disease (Fuentealba exclusions)
  • Pregnancy (elective use; obstetrics uses TPE only for specific diseases)
  • Recent myocardial infarction (<90 days) or stroke pending individual clearance
  • Fibrinogen too low to complete a session without product support

Risk Mitigation Strategies

  • Hold ACE inhibitors 24 hours: Prevents membrane-related bradykinin shock on DFPP/membrane TPE circuits.

  • Ionized calcium protocol: Replace calcium during citrate runs; check magnesium. Targets citrate tetany and arrhythmia.

  • Fibrinogen floor: Delay the next session or supplement if fibrinogen is <1.0–1.5 g/L; avoids post-procedure bleeding.

  • Peripheral veins first: Dual large-bore peripheral needles avoid central-line infection in elective users.

  • Albumin rather than donor plasma: Cuts transfusion reactions and pathogen exposure when clotting-factor replacement is not required.

  • Immunoglobulin G and vaccine timing: Recheck IgG after a cluster of TPE sessions; avoid live vaccines while IgG is still low.

  • Session length and posture: Longer DFPP runs need pressure checks and slow return to standing to limit hypotension.

Therapeutic Protocol

  • Longevity TPE (Kiprov / Circulate): About 1–1.5 plasma volumes with 5% albumin; six sessions (two in one week, then monthly, or six monthly). Fuentealba’s largest clock move was biweekly TPE plus immunoglobulin, not more-frequent TPE alone.

  • Disease TPE (ASFA-style): Daily or every-other-day 1–1.5 volume exchanges for a defined course (e.g., five to seven sessions), then stop or taper with the disease.

  • DFPP / cascade / INUSpheresis: 0.75–1.5 plasma volumes; fractionator chosen for lipids versus antibodies; little or no albumin. Session often 3–4 hours. Not the protocol used in the 2025 clock randomized trial.

  • Time of day: Morning or midday, 2–4 hours, after food and hydration; not a timed drug dose.

  • Protein recovery, not a drug half-life: Fibrinogen half-life ~3–4 days (check before close-spaced sessions); IgG ~21 days; albumin ~19 days. Split “dosing” means spacing sessions, not splitting a daily milligram dose.

  • Genetics: No validated pharmacogene dictates TPE versus DFPP. APOE4 is relevant to Alzheimer’s risk, not to machine choice.

  • Sex: No human dosing split; mouse dilution lifespan effects have been sex-specific.

  • Age: Elective trials enrolled people ≥50; older veins and citrate sensitivity dominate practical limits.

  • Baseline labs: High LDL-C/Lp(a) favors DFPP-as-lipid-apheresis; a dilution goal favors albumin-TPE. Low IgG or fibrinogen argues against a dense TPE cluster.

  • Heart, kidney, and infection status: Unstable cardiorespiratory disease and active infection are protocol stops, not dose tweaks.

Discontinuation & Cycling

  • Not a lifelong drug: Both procedures are intermittent. Proteins rebound; any biomarker shift can fade (Fuentealba clocks were smaller by the last draw).

  • No classic withdrawal syndrome: Stopping does not cause a recognized abstinence state. Removed antibodies and lipids return toward the person’s baseline production rate.

  • No taper of a molecule: “Tapering” means fewer sessions per month, not cutting a milligram dose. Fibrinogen and IgG are the labs that gate the next run.

  • Cycling: Longevity clinics often cycle (e.g., six sessions then months off) because rebound is expected and because more-frequent TPE was not clearly better on clocks than monthly TPE.

  • After a bleed or infection: Hold until fibrinogen, counts, and infection clear; then restart only if the indication remains.

Sourcing and Quality

  • Accredited apheresis unit: Hospital or dedicated apheresis clinic with trained operators beats non-hospital “blood purification” venues without emergency backup.

  • Machine class: Centrifugal TPE (common in the U.S.) versus membrane DFPP (Japan, Europe, some dialysis units). The 2025 aging randomized trial used centrifugal TPE plus albumin, not DFPP.

  • Albumin product: 5% human albumin from a licensed fractionator; pathogen-reduced products where available. Fresh frozen plasma only when clotting proteins must be replaced.

  • Fractionator identity: Evaflux/Rheofilter (or IN300 for branded INUSpheresis) pore size should match the goal (lipids versus immunoglobulins). Wrong filter means the wrong proteins leave.

  • Conflicted vendors: Circulate/Global Apheresis sell elective TPE; Asahi Kasei sells DFPP filters; Grifols sells albumin. Public payers save plasma with DFPP and rarely cover elective longevity TPE.

Practical Considerations

  • Time to effect: Lipids and fibrinogen fall during the session. Immune-protein nadirs lag hours to a day. AMBAR functional differences accrued over months. Clock changes in Fuentealba were early and then attenuated.

  • Common pitfalls: Treating plasma donation (no replacement) as if it were albumin-TPE; using DFPP and expecting the Conboy dilution effect; stacking sessions before fibrinogen recovers; leaving an ACE inhibitor on for a membrane run.

  • Regulatory status: Devices are cleared for listed apheresis indications. Elective longevity TPE or DFPP is off-label. Young-plasma products have drawn Food and Drug Administration consumer warnings.

  • Cost and access: U.S. out-of-pocket TPE is often about $5,000–$15,000 per session; a six-session series reaches tens of thousands. DFPP usually uses less albumin and can cost substantially less.

Interaction with Foundational Habits

  • Sleep: Indirect. Citrate tetany, histamine-type reactions, or post-session fatigue can fragment the following night; morning sessions leave recovery to the afternoon. No evidence of improved sleep architecture.

  • Nutrition: Direct. Hydrate and eat before the run. Calcium- and magnesium-replete intake supports citrate circuits. TPE drops albumin-bound micronutrients until diet or the replacement fluid restores them; DFPP spares more albumin.

  • Exercise: Direct, short-term blunting of high-load training. Fibrinogen and factor XIII are low for ~48 hours — contact sport, max lifts, and invasive dental work sit in that window. Lipoprotein-apheresis DFPP is compatible with ongoing training once clotting labs recover.

  • Stress management: Indirect. Needle access and 2–4 hours on a machine raise sympathetic tone in some people; there is no established cortisol-lowering protocol effect. Familiar operators and peripheral access reduce procedural stress.

Monitoring Protocol & Defining Success

Baseline work before a first elective session includes vein assessment, complete blood count, chemistry with ionized calcium and magnesium, fibrinogen, immunoglobulin G, albumin, lipid panel with lipoprotein(a), high-sensitivity C-reactive protein, and estimated glomerular filtration rate (eGFR, a creatinine-based kidney-filter estimate). An electrocardiogram is reasonable if citrate will be used. Repeat clotting and chemistry the day after a first run, then before each close-spaced session.

Ongoing cadence in aging TPE protocols is pre-session, after session 3–4, after session 6, then every 3–6 months. Lipoprotein-apheresis DFPP is weekly or biweekly with lipids drawn immediately before and after a session. Lipid success is a documented per-session LDL-C or Lp(a) drop. Dilution/longevity success is less clear: clocks have moved without a declared functional gain, so energy, training recovery, infections, and the labs below outrank a single biological-age number.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fibrinogen 2.0–4.0 g/L; hold session if <1.0–1.5 g/L Gates bleeding risk after either modality Conventional lab range similar; trough is 24–48 h post-session
Ionized calcium 1.15–1.30 mmol/L Citrate tetany and arrhythmia Not total calcium; replace on-circuit if falling
Magnesium 2.0–2.4 mg/dL (functional often ≥2.0) Co-depleted with citrate Conventional lower bound is often 1.6–1.8 mg/dL
Immunoglobulin G Keep >500–600 mg/dL after TPE clusters Infection risk after bulk exchange DFPP spares more IgG depending on fractionator
Albumin 4.0–5.0 g/dL Keeps fluid in vessels; dilution quality TPE replaces with 5% albumin; DFPP should not crash albumin
LDL-C Individual target, often <70 mg/dL if high risk Confirms DFPP lipid effect Draw pre and post session; rebound is expected
Lipoprotein(a) Change from own baseline if no lab “optimal” Genetic particle DFPP actually removes Report in nmol/L when possible
High-sensitivity CRP <1.0 mg/L (many functional targets <0.5) Inflammation trend Modest mean drop in apheresis meta-analysis; conventional upper bound is often <3.0 mg/L
Complete blood count Hemoglobin ≥10–11 g/dL to start; watch platelets Anemia and centrifugal platelet dip Fasting not required
eGFR Track own baseline; conventional ≥60 mL/min/1.73 m² Volume and citrate handling Not a DFPP efficacy marker

Qualitative markers:

  • Energy and orthostatic symptoms in the 24 hours after a session
  • Training quality 48 hours later (proxy for clotting recovery)
  • Bruising, needle-site issues, tingling around mouth or fingers
  • Infections or poor vaccine responses over a treatment season
  • Subjective cognitive clarity only as a secondary note, not a success metric

Emerging Research

  • Fuentealba / Circulate TPE clock trial: Published 2025 as NCT06534450; n ≈ 42, sham-controlled centrifugal TPE ± immunoglobulin. Follow-up that adds hard functional endpoints would strengthen or weaken the longevity case.

  • Borsky donation plasmapheresis: Completed as NCT05004220 and published 2025; no-replacement protocol associated with faster clocks — the main negative control for “just remove plasma.”

  • DFPP for microplastics and PFAS: NCT07658443 (enrolling by invitation, n = 20) measures pre/post particle and PFAS change after IN300 DFPP; a null result would undercut detox marketing.

  • TPE versus DFPP immune phenotypes: NCT04742374 compared single exchange and DFPP on lymphocyte phenotypes in chronic inflammatory demyelinating polyneuropathy (completed, n = 8).

  • Albumin versus no albumin for aging markers: NCT04897113 (status unknown) was designed to test replacement fluid directly — the comparison the clock literature now needs.

  • Mouse-to-human dilution: Conboy-lab saline-albumin exchange (Mehdipour et al., 2020) still lacks a DFPP arm in animals, which could show whether sparing mid-size proteins erases the rejuvenation signal.

Conclusion

Double filtration and bulk plasma exchange are related machines that remove different things. Bulk exchange plus albumin matches the mouse dilution experiments and the human dementia and biological-age-marker studies. Double filtration lowers large lipid particles and big proteins while sparing most albumin, using less replacement fluid and, in disease cohorts, causing fewer allergic events. Those are different jobs. Marketing both as nonspecific detoxification hides that difference.

The strongest replicated human benefit for double filtration is a large, short-lived drop in low-density lipoprotein and lipoprotein(a). For albumin-replacement exchange outside classic autoimmune disease, the strongest signal is slower decline on named function scales in moderate Alzheimer’s disease, in work funded by an albumin maker. Marker “rejuvenation” after elective exchange is unvalidated and sits beside a donor study in which removing plasma without putting albumin back moved markers in the opposite direction. No study has shown that healthy people live longer, stay stronger, or avoid disease because they chose one machine over the other.

Harms are documented: citrate-related low blood calcium and muscle cramp, a sharp drop in clotting proteins, antibody-protein loss with infection in intensive courses, replacement-fluid allergy, and needle-site problems. Elective series in selected older adults look safer than hospital neurology exchange. The society whose members bill these procedures issues indication lists; filter makers, albumin makers, and longevity clinics all have revenue tied to the answer. What remains is a comparison of what each procedure removes, in whom, with which replacement fluid — not a settled preference for either method.

Top - Benefits - Risks - Protocol